antiviral | Medical XPRT
News
-
Report On Activities For The Quarter Ended 31 March 2022
During the quarter ended 31 March 2022 Biotron Limited (‘Biotron’ or ‘the Company’) achieved key outcomes including: Confirmed and extended previous findings on the effectiveness of Biotron's lead antiviral drug BIT225 ...
Equipment & Solutions
-
Showcase
RealFast Assay
The IL28B RealFast™ Assay helps to predict the success of antiviral therapy and sustained virologic response (SVR) in Hepatitis C Virus (HCV) infected patients.
